Q-omics provides the consensus-scored VAT1L profile across patient tissues and cancer cell-line models. VAT1L expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, VAT1L is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, VAT1L protein abundance shows 18,928 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BRCA, COAD, and GBM as cancer lineages where VAT1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VAT1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VAT1L survival associations across molecular data types. VAT1L RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VAT1L RNA expression–survival associations across cancer types. High VAT1L expression shows unfavorable associations in BRCA, KIRP, LIHC and MESO, but favorable associations in KICH and SKCM. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for VAT1L RNA expression.
This table summarizes VAT1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for VAT1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VAT1L shows lower tumor expression in COAD, KIRC, KIRP, UCEC, STAD and BRCA. The COAD box plot shows higher VAT1L RNA expression in normal versus tumor tissue (log2 FC = −1.431, t-test p < 0.001).
This table shows molecular features associated with VAT1L in patient tissues and cancer cell lines. In patient samples, VAT1L shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, VAT1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
